ProCE Banner Activity

CME

Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC

Video

On-demand webcast of expert faculty presentation and case discussion on the evolving treatment landscape for patients with EGFR-mutated advanced and metastatic NSCLC, from CCO’s expert perspectives symposium at ASCO 2024.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: June 12, 2024

Expiration: June 11, 2025

Share

Faculty

Nicolas Girard

Nicolas Girard, MD, PhD

Professor
Chair of Medical Oncology
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Universite Paris-Saclay
Paris, France

Natasha Leighl

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Karen Reckamp

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director of Clinical Research
Professor of Medicine
Cedars Sinai
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Boehringer Ingelheim Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This program is intended for oncologists, and members of the multidisciplinary healthcare team that are involved in the care of patients with locally advanced or metastatic non-small cell lung cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with advanced non-small cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Apply to clinical practice the latest disease management strategies from ongoing clinical trials of targeted therapies, including recent updates to guideline recommendations for individualizing a therapeutic strategy for the management of locally advanced and metastatic non-small-cell lung cancer

  • Determine if individual patients with locally advanced and metastatic non-small-cell lung cancer are candidates for an ongoing investigational clinical trial of a targeted therapy in the first or subsequent line based on need, due to inability or choice not to take standard-of-care treatments, unique mechanism of action, or the presence of specific EGFR genetic alterations

  • Identify patients with EGFR-mutated locally advanced and metastatic non-small-cell lung cancer that has progressed on third-generation EGFR TKI therapy who may be eligible for ongoing clinical trials evaluating combinations of currently available and novel targeted therapies, and counsel patients on the investigational agents or drug combinations and the potential for trial enrollment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Nicolas Girard, MD, PhD

Professor
Chair of Medical Oncology
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Universite Paris-Saclay
Paris, France

Nicolas Girard, MD, PhD: researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Hoffmann-La Roche, Janssen, LEO Pharma, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Sanofi, Sivan; consultant: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Hoffmann-La Roche, Ipsen, Janssen, LEO Pharma, Lilly, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Pierre Fabre, Sanofi, Takeda; data and safety monitoring board: Hoffmann-La Roche.

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Natasha Leighl, MD, MMSc, FRCPC, FASCO: researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Inivata/NeoGenomics, Lilly, Merck Sharp & Dohme, Pfizer; consultant/advisor/speaker: AstraZeneca, Guardant Health, Janssen, Merck Sharp & Dohme, Roche, Sanofi.

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director of Clinical Research
Professor of Medicine
Cedars Sinai
Los Angeles, California

Karen Reckamp, MD, MS: consultant/advisor/speaker: Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Novacure, Novartis; researcher: Blueprint, Daiichi Sankyo, Elevation Oncology, Genentech, Janssen.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 12, 2024, through June 11, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport 

 

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.